• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A New Proposal for SSRI Withdrawal
RESEARCH UPDATE

A New Proposal for SSRI Withdrawal

July 3, 2019
Greg Sazima, MD and Chris Aiken, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Drs. Sazima and Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Horowitz MA and Taylor D, Lancet Psychiatry, March 2019, published online


Type of Study: Literature review and clinical guideline


Withdrawal problems rank among patients’ top concerns with antidepressants. They include insomnia, flu-like symptoms, irritability, distractibility, and unusual sensory experiences such as “brain zaps.” To avoid this syndrome, most clinicians taper antidepressants linearly, lowering the dose by a fixed amount at a regular rate. For example, a typical linear taper of citalopram 30 mg daily might proceed like this: citalopram 20 mg daily for 1 week, 10 mg daily for 1 week, then stop. A new study suggests we might need to rethink that practice.


The authors examined clinical and biological research on tapers of serotonergic antidepressants. Their review included six major clinical trials examining SSRI and SNRI tapers, covering a total of 1,687 patients. The clinical outcomes on linear tapers were problematic. In one study, 60% of patients required 4 months or more to taper. In another, patients had particular difficulty at the final tail of the taper. They stalled when the taper reached half of the minimum therapeutic dose for depression (eg, when citalopram reached 10 mg daily). Only 37% were able to complete the taper beyond that point.


To better understand these problems, the authors looked at PET scan data. In line with the clinical findings, there was a dramatic fall in serotonin transporter inhibition when linear tapers reached half of the minimum therapeutic dose for depression. Inhibition of the serotonin transporter is the principal mechanism of SSRIs, and changes in that inhibition are thought to contribute to serotonergic withdrawal symptoms.


The authors proposed a new tapering strategy to prevent this dramatic fall: the “hyperbolic taper.” In this taper, the SSRI is lowered with a long tail of incrementally smaller dose reductions. With this strategy, the serotonin inhibition would fall linearly as the SSRI is tapered at an increasingly slower rate. Theoretically, this “hyperbolic taper” could prevent serotonin withdrawal symptoms. The authors recommend the same strategy with fluoxetine, although the risk of withdrawal problems is lower with this SSRI because of its long half-life.


TCPR’S TAKE
Tapers with a long tail have been used successfully with benzodiazepines, and the clinical and biological data presented here suggest they may be preferable with serotonergic antidepressants as well. Although the idea lacks clinical proof, so does current practice, and a “hyperbolic taper” is worth trying in patients who have trouble with serotonin withdrawal.




The Hyperbolic Taper for SSRIs


  1.  Lower to the minimum dose
    Reduce the dose to the minimum suggested in the table on this page if not already there (eg, citalopram 20 mg). The dose can be reduced linearly at this stage because the main risk is depressive relapse, not serotonin withdrawal. Consider the patient’s history, including risk of relapse and prior response to lower doses, in determining the rate of the taper. Lowering every 1–2 weeks is reasonable for most patients.

  1.  Assess baseline symptoms
    Check if the patient is having any SSRI withdrawal symptoms at baseline (see www.thecarlatreport.com/serotonin).

  1.  Lower for one month and reassess
    Now move to the first tapering dose in the table (eg, citalopram 10 mg). After a month, reassess for SSRI withdrawal symptoms.

  2.  Start the long-tail taper
    The doses for each step of the final taper are listed in the table (eg, citalopram 5 mg, then 3.4 mg). How quickly you go down at each step depends on how sensitive the patient is to withdrawal; your assessment of symptoms at baseline and one month later will give you a sense of this. At a minimum, allow 1 week between each step; 2 weeks is a rough average, and sensitive patients may require 6 weeks between each step.





Table: SSRI Tapers



Click to view full-size PDF.




For more on this subject, listen to our podcast, “SSRI Withdrawal”


General Psychiatry Research Update
KEYWORDS pharmacology pharmacology-tips ssris withdrawal
    Greg Sazima, MD

    A Possible Option in Opioid-Related Harm Reduction

    More from this author
    Aiken eic 150x150
    Chris Aiken, MD

    Ketamine Assisted Therapy Part I

    More from this author
    www.thecarlatreport.com
    Issue Date: July 3, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Side Effects Part I, TCPR, June/July 2019
    Mood Stabilizers and Stroke Risk in Bipolar Disorder
    Lithium in Geriatric Depression
    New Augmentation Strategies in OCD
    Esketamine Gets FDA Approval
    Risk Evaluation and Mitigation Strategy (REMS) Programs
    Medication Side Effects: Nausea, Sweating, and Dry Mouth
    Are Auditory Hallucinations Ever Normal?
    Brexanolone (Zulresso) for Postpartum Depression
    A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness
    A New Proposal for SSRI Withdrawal
    SSRI withdrawal symptoms
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.